



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/629,823	07/30/2003	Hassan Hajjaj	88265-6684 7287 EXAMINER		
28765 .7	7590 11/26/2004				
WINSTON & STRAWN			SRIVASTAVA, KAILASH C		
PATENT DEPARTMENT 1400 L STREET, N.W.			ART UNIT	PAPER NUMBER	
	N, DC 20005-3502	•	1651		
·			DATE MAILED: 11/26/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No	. 7	Applicant(s)			
Office Action Summary		10/629,823		HAJJAJ ET AL.			
		Examiner		Art Unit			
•		Dr. Kailash C. S	srivastava :	1651			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status							
1)⊠	1) Responsive to communication(s) filed on 16 September 2004.						
2a) <u></u> ☐	This action is FINAL . 2b)⊠ This action is non-final.						
3)	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4) ⊠ Claim(s) 10-26 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) 10-26 are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
2) Notice 3) Infor	nt(s) ce of References Cited (PTO-892) ce of Draftsperson's Patent Drawing Review (F mation Disclosure Statement(s) (PTO-1449 or er No(s)/Mail Date	PTO/SB/08) 5)	Interview Summary (I Paper No(s)/Mail Dat Notice of Informal Pa Other:				

DETAILED ACTION

- 1. Applicants' amendment filed 16 September 2004 in response to Office Action dated 18 August 2004 is acknowledged and entered.
- 2. Examiner re-iterates that the correct Art Unit location of your application in the USPTO is 1651, not 1645 as noted on the response filed 16 September 2004. To aid in correlating any papers for this application, all further correspondence regarding this application should be directed to Examiner Kailash C. Srivastava in Art Unit 1651.

CLAIMS STATUS

- 3. Claims 1-9 have been cancelled.
- 4. Claims 14-26 have been added.
- Claims 10-11 have been amended
- 6. Claims 10-26 are pending.

Restriction/Election

7. Applicants' election with traverse of Group II, Claims 10-11 with newly presented product by-process claims 14-24 filed 16 September 2004 is acknowledged and entered. Applicants' traversal is on the grounds that the amended claims 10-11 should be examined together with newly presented claims 14-24 because all the claims belong in the same group and are product by-process claims and there is no additional burden on the examiner to examine Claims 10-11 along with newly presented Claims 14-24.

Applicants' arguments, see under Remarks Page 6, Line 3 to Page 7, Line 8 in response filed 16 September 2004, with respect to joining amended Claims 10-11 with newly presented Claims 14-24 have been fully considered and are persuasive. The restriction requirement in the Office Action mailed 18 August 2004 has been withdrawn.

Accordingly, Claims 10-11 and newly presented claims 14-24 will be examined together as one invention.

- 8. A further review of all pending Claims, however, necessitates Restriction of Claims 10-26 to one of the following inventions under 35 U.S.C. §121:
- Group I, consisting of amended claims 10-11 and newly presented Claims 14-24 drawn to a product by process, classified under Class 424, Subclass 195.15.

 Group II- Claims 12-13 and newly presented Claims 25-26 drawn to a method to apply a composition to inhibit cholesterol production in a subject, classified under Class 424, Subclass 780.

Inventions in Groups I and II are related to each other as product and use thereof. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product [MPEP § 806.05(h)]. The process of inhibiting cholesterol may also be achieved with a number of pharmaceuticals available in the market place. Similarly, the food/pharmaceutical product claimed in invention of Group II is applicable as a nutraceutical composition.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, and their recognized diverse subject matter, restriction for examination purposes as indicated is proper.

9. Applicants are advised that a reply to this requirement must include an identification of an invention elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicants will be entitled to consideration of additional claims which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR §1.141. Currently, Claim 10 is generic claim. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

- 10. Applicants are reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR §1.48(b). Any amendment of inventorship must be accompanied by a petition under 37 CFR §1.48(b) and by the fee required under 37 CFR §1.17(I).
- 11. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR §1.116; amendments submitted after allowance are governed by 37 CFR §1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR §1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. §101, §102, §103, and §112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.** Further, note that the prohibition against double patenting rejections of 35 U.S.C. §121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP §804.01.

12. Any inquiry concerning this communication, or earlier communications from the examiner should be directed to Examiner Kailash C. Srivastava whose telephone number is (571) 272-0923. The examiner can normally be reached on Monday to Thursday from 8:15 A.M. to 6:45 P.M. (Eastern Standard or Daylight Savings Time).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Michael Wityshyn, can be reached on (571) 272-0926 Monday through Thursday. The fax phone number for the organization where this application or proceeding is assigned is (703)-872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-0196.

Kailash C. Srivastava, Ph.D.

Patent Examiner Art Unit 1651

(571) 272-0923

November 24, 2004

Railones

RALPH GITOMER PRIMARY EXAMINER GROUP 1200